Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery
Kirsten McAulay, Alan Bilsland, Marta Bon
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1366-1366
Open Access | Times Cited: 22

Showing 22 citing articles:

Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 42
Fragment-to-Lead Medicinal Chemistry Publications in 2022
Andrew J. Woodhead, Daniel A. Erlanson, Iwan J. P. de Esch, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2287-2304
Closed Access | Times Cited: 15
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers
James Cregg, Kristóf Póta, Aidan C.A. Tomlinson, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 1
The current role and evolution of X-ray crystallography in drug discovery and development
Vanessa Bijak, Michal Szczygiel, Joanna Lenkiewicz, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 11, pp. 1221-1230
Open Access | Times Cited: 18
Covalent hits and where to find them
Simon C. C. Lucas, J. Henry Blackwell, Sarah H. Hewitt, et al.
SLAS DISCOVERY (2024) Vol. 29, Iss. 3, pp. 100142-100142
Open Access | Times Cited: 6
Covalent chemical probes for protein kinases
Ricardo Augusto Massarico Serafim, Lisa Haarer, Júlia G. B. Pedreira, et al.
Current Research in Chemical Biology (2023) Vol. 3, pp. 100040-100040
Open Access | Times Cited: 15
Technologies for Direct Detection of Covalent Protein–Drug Adducts
Elma Mons, Robbert Q. Kim, Monique P. C. Mulder
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 547-547
Open Access | Times Cited: 14
An Antiherpesviral Host-Directed Strategy Based on CDK7 Covalently Binding Drugs: Target-Selective, Picomolar-Dose, Cross-Virus Reactivity
DongHoon Yu, Sabrina Wagner, Martin Schütz, et al.
Pharmaceutics (2024) Vol. 16, Iss. 2, pp. 158-158
Open Access | Times Cited: 5
Covalent inhibitors: An ambitious approach for the discovery of newer oncotherapeutics
Rameshwar S. Cheke, Prashant S. Kharkar
Drug Development Research (2023) Vol. 85, Iss. 1
Open Access | Times Cited: 11
Data-oriented protein kinase drug discovery
Elena Xerxa, Jürgen Bajorath
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116413-116413
Open Access | Times Cited: 4
Data-Driven Global Assessment of Protein Kinase Inhibitors with Emphasis on Covalent Compounds
Elena Xerxa, Filip Miljković, Jürgen Bajorath
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7657-7665
Closed Access | Times Cited: 10
Probabilistic generative transformer language models for generative design of molecules
Lai Wei, Nihang Fu, Yuqi Song, et al.
Journal of Cheminformatics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 9
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53
Theresa Klett, Martin Schwer, Larissa N. Ernst, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 2653-2679
Open Access | Times Cited: 3
Covalent fragment approaches targeting non-cysteine residues
Noémi Csorba, Péter Ábrányi‐Balogh, György M. Keserü
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 802-816
Open Access | Times Cited: 7
Exploring Extended Warheads of Reversible and Irreversible Cysteine-Targeted Covalent Kinase Inhibitors
Zheng Zhao, Philip E. Bourne
(2024)
Open Access | Times Cited: 2
bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements
Jay Yang, Yudai Tabuchi, Riku Katsuki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3525-3525
Open Access | Times Cited: 5
Data Sets of Human and Mouse Protein Kinase Inhibitors With Curated Activity Data Including Covalent Inhibitors
Elena Xerxa, Jürgen Bajorath
Future Science OA (2023) Vol. 9, Iss. 9
Open Access | Times Cited: 2
Discovery of RMC-6291, a potent, orally bioavailable, covalent RAS(ON) G12C selective inhibitor
James Cregg, Kristóf Póta, Adrian L. Gill, et al.
Elsevier eBooks (2024), pp. 277-308
Closed Access
Covalent Fragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by Nucleophilic Aromatic Substitution
Theresa Klett, Jason Stahlecker, Simon Jaag, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 12, pp. 3984-3999
Open Access
Nrf2-Independent Anti-Inflammatory Effects of Dimethyl Fumarate: Challenges and Prospects in Developing Electrophilic Nrf2 Activators for Neurodegenerative Diseases
Yasuhiko Izumi, Yutaka Kōyama
Antioxidants (2024) Vol. 13, Iss. 12, pp. 1527-1527
Open Access
Exploring Extended Warheads toward Developing Cysteine-Targeted Covalent Kinase Inhibitors
Zheng Zhao, Philip E. Bourne
Journal of Chemical Information and Modeling (2024)
Open Access
Introducing covalent warheads on spirocyclic sp2–sp3 fragments by innate C–H functionalization
M. Martinelli, Christophe Giorgiutti, Thomas C. Fessard, et al.
Organic & Biomolecular Chemistry (2023) Vol. 21, Iss. 46, pp. 9230-9235
Closed Access
Page 1

Scroll to top